Pharmos, Bausch & Lomb Pharmaceuticals regulatory update

After meeting with the FDA to discuss the status of the NDA submission for Lotemax, a steroid for eye inflammation, PARS and B&L said they will accelerate a previously planned Phase IV trial in uveitis, a severe inflammation, to provide the agency with additional data to support a broad class label for the drug. ...